Pralsetinib

small molecule

Identifier: CI-DRUG-00000486
Entity page: /drug/pralsetinib ↗
Edges: 60

Neighbours: 17 cancers3 genes2 variants10 trials2 approvals
Drawn: 34 of 34 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Pralsetinib approved for …APPROVED_FOR4 of 2
→ approved for	Lung Non-Small Cell Carcinomasubtype	supports	FDA ORIG	Lung Non-Small Cell Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Malignant Thyroid Gland Neoplasmcancer	supports	FDA ORIG

Pralsetinib predicts response to …PREDICTS_RESPONSE_TO2 of 2
← predicts response to	RET Fusionfusion 2 source records aggregated	sensitivity	A	Lung Non-Small Cell Carcinoma,Malignant Thyroid Gland Neoplasm	2	Curated	civic	graph →
← predicts response to	RET M918TSNV	sensitivity	D	Malignant Neoplasm	1	Curated	civic	graph →

Pralsetinib predicts response to …PREDICTS_RESPONSE_TO2 of 2

← predicts response to

RET Fusionfusion

2 source records aggregated

sensitivity

Lung Non-Small Cell Carcinoma,Malignant Thyroid Gland Neoplasm

Curated

Pralsetinib targets …TARGETS3 of 3
→ targets	KIF5B	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	CCDC6	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	RET	—	INHIBITOR	—	1	Curated	chembl	graph →

Pralsetinib investigated for …INVESTIGATED_FOR6 of 6
→ investigated for	Malignant Thyroid Gland Neoplasmcancer	supports	A	Malignant Thyroid Gland Neoplasm	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Malignant Neoplasmcancer_family	supports	D	Malignant Neoplasm	1	Curated	civic	graph →
→ investigated for	Thyroid Gland Neoplasmsubtype	unknown	2	Thyroid Gland Neoplasm	1	Curated	chembl	graph →

Pralsetinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 32show all (up to 200)
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 7 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Thyroid Gland Medullary Carcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Thyroid Gland Medullary Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adenocarcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Bronchogenic Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Bronchogenic Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasmcancer_family 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasm by Site 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm by Site	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Respiratory System Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Respiratory System Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Thoracic Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Thoracic Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Thyroid Gland Neoplasmsubtype 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Thyroid Gland Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cholangiocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Colon Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colon Neoplasm	1	Observed	clinicaltrials	graph →

Pralsetinib studied in …STUDIED_INderived10 of 15show all (up to 200)
→ studied in	NCT04302025Phase 2 · recruiting A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) · 15 trials list this drug (8 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04589845Phase 2 · active not recruiting Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study · 15 trials list this drug (8 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07704658Phase 4 · recruiting Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors · 15 trials list this drug (8 active)	—	—	Lung Non-Small Cell Carcinoma,Malignant Thyroid Gland Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05525858recruiting KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II · 15 trials list this drug (8 active)	—	—	Malignant Neoplasm,Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 15 trials list this drug (8 active)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04222972Phase 3 · terminated A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) · 15 trials list this drug (8 active)	—	—	Neoplasm,Neoplasm by Site,Head and Neck Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07418879NA · not yet recruiting A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC · 15 trials list this drug (8 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07010393Phase 4 · not yet recruiting Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · 15 trials list this drug (8 active)	—	—	Thyroid Gland Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03037385Phase 1/Phase 2 · completed Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors · 15 trials list this drug (8 active)	—	—	Neoplasm,Neoplasm by Site,Digestive System Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 15 trials list this drug (8 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths